Previous Close | 4.6300 |
Open | 4.7000 |
Bid | 3.4000 x 900 |
Ask | 5.2000 x 1100 |
Day's Range | 4.4000 - 4.9900 |
52 Week Range | 1.6850 - 8.0400 |
Volume | |
Avg. Volume | 133,772 |
Market Cap | 319.128M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
BOSTON & LAUSANNE, Switzerland, March 28, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Acutis Diagnostics, a specialized medical laboratory, will use SOPHiA DDM™ to develop a new genomic assay. This new next-generation sequencing (NGS) test will build on Acutis Diagnostics’ track record of approved lab-developed tests that support clinical trials, cancer research and treatment.
BOSTON & LAUSANNE, Switzerland, March 14, 2023--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and the leader in data-driven medicine, is partnering with Agilent to offer a comprehensive solution for cancer analysis.
BOSTON & LAUSANNE, Switzerland, March 07, 2023--SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced financial results for its fourth quarter and full fiscal year ended December 31, 2022.